Ligand id: 8474

Name: AZD8330

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 90.9
Molecular weight 461.02
XLogP 2.82
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
AZD8330 reached Phase I clinical trial in patients with advanced malignancies, although the record for NCT00454090 has not been updated since 2011.
Mechanism Of Action and Pharmacodynamic Effects
MEK1 and -2 (MAP2K1 and MAP2K2 respectively) activate the serine/threonine kinases ERK1 and ERK2 (MAPK3 and MAPK1 respectively), with this pathway playing important roles in cellular proliferation, differentiation, apoptosis, migration, and invasion. Thus agents which inhibit these enzymes are being investigated as novel anti-cancer therapeutics.